The story · written by opus-5.5,
Switzerland did not legalise cannabis in 2023. It began selling it lawfully to a limited number of adults, as science. Distribution started in Basel in January 2023, the first of a series of city trials that the Federal Office of Public Health has authorised one by one.
The legal basis
Since 15 May 2021 an amendment to the Narcotics Act has allowed scientific pilot trials with the controlled sale of cannabis for adult non-medical use. The provision is limited to ten years, and each trial is limited to a place and a period. The purpose is to gather evidence on the advantages and drawbacks of controlled access before parliament decides on a permanent rule. Medical use on prescription is outside the trials.
For participants the difference from everyday law is concrete. They can lawfully buy products whose quality is controlled, from staff trained to explain the risks. The supply chain is monitored from seed to sale, and advertising is banned completely.
The trials
| Trial | Place | Model |
|---|---|---|
| WeedCare | Canton of Basel-Stadt | Pharmacies |
| ZüriCan | City of Zurich | Pharmacies, social clubs and drug counselling centres |
| SCRIPT | Bern, Biel, Lucerne | Non-profit sale in pharmacies, with counselling |
| Cann-L | City of Lausanne | Non-profit sale |
| La Cannabinothèque | Vernier, Geneva | Members’ site with entrance control |
| Grashaus Projects | Liestal and Allschwil | Points of sale |
| Cannabis Research Zürich | Canton of Zurich | Study of social and economic effects |
| CanLeg | Canton of St. Gallen | Randomised controlled trial |
SCRIPT alone has 1,091 participants. It is a randomised study: a control group keeps buying on the illegal market while the others buy flowers, resin, e-liquid or oil grown in Switzerland under organic rules. Its coordinator’s project had been held up for more than ten years by political and legal disputes before the 2021 amendment opened the way.
Outside the trials
Everyone else stayed under the ordinary rules. As swissinfo summarised in July 2023, selling or buying cannabis with more than 1% THC is not allowed. A parliamentary initiative to regulate the market had by then been accepted by both chambers and sent to a subcommittee for drafting.
Why the index moved
Access rose from 1 to 2. Before 2023 the only lawful cannabis was medical. The trials added a second lawful source for adults who use it for pleasure, but only for registered participants in the places that run one, which is why the step is one point and not more. No other score moved, since possession, growing and supply outside the trials are treated as before.[1][2][3]
Score by segment 0 to 10
- Possession · 25%4 → 4
- Personal cultivation · 25%1 → 1
- Punishment & enforcement · 20%5 → 5
- Sharing & gifting · 10%3 → 3
- Consumption · 10%2 → 2
- Legal access · 10%1 → 2+1
The bar shows the score after the change; the tick marks where it stood before. The scores after the change are Switzerland's current scores.
References
- Bundesamt für Gesundheit — Pilotversuche mit Cannabisarchived
- Federal Office of Public Health — Overview of authorised pilot trials with cannabisarchived
- SWI swissinfo.ch — Cannabis: Die Schweiz experimentiert mit der kontrollierten Abgabe (11 July 2023)archived
- Prohibition Partners — Switzerland adult-use overviewarchived
- Wikipedia — Cannabis in Switzerlandarchived
Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.